Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease

Daisy J.A. Janssen, Sabrina Bajwah, Michele Hilton Boon, Courtney Coleman, David C. Currow, Albert Devillers, Chantal Vandendungen, Magnus Ekström, Ron Flewett, Sarah Greenley, Mai-Britt Guldin, Cristina Jácome, Miriam J. Johnson, Geana Paula Kurita, Matthew Maddocks, Alda Marques, Hilary Pinnock, Steffen T. Simon, Thomy Tonia, Kristoffer Marsaa
European Respiratory Journal 2023 62: 2202014; DOI: 10.1183/13993003.02014-2022
Daisy J.A. Janssen
1Department of Research & Development, Ciro, Horn, The Netherlands
2Department of Health Services Research and Department of Family Medicine, Care and Public Health Research Institute, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daisy J.A. Janssen
  • For correspondence: daisyjanssen@ciro-horn.nl
Sabrina Bajwah
3Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sabrina Bajwah
Michele Hilton Boon
4WiSE Centre for Economic Justice, Glasgow Caledonian University, Glasgow, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Courtney Coleman
5European Lung Foundation, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Currow
6Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Devillers
7Association Belge Francophone contre la Fibrose Pulmonaire (ABFFP), Rebecq, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Vandendungen
7Association Belge Francophone contre la Fibrose Pulmonaire (ABFFP), Rebecq, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Ekström
8Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine, Allergology and Palliative Medicine, Lund, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Magnus Ekström
Ron Flewett
9Pulmonary Fibrosis Trust, Lichfield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Greenley
10Institute for Clinical and Applied Health Research, Hull York Medical School, University of Hull, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mai-Britt Guldin
11Research Unit for General Practice, Aarhus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Jácome
12CINTESIS@RISE, Department of Community Medicine, Health Information and Decision, Faculty of Medicine of University of Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina Jácome
Miriam J. Johnson
13Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geana Paula Kurita
14Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
15Multidisciplinary Pain Centre, Department of Anaesthesiology, Pain and Respiratory Support, Neuroscience Centre and Palliative Research Group, Department of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Maddocks
3Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alda Marques
16Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA) and Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilary Pinnock
17Allergy and Respiratory Research Group, Usher Institute, University of Edinburgh, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hilary Pinnock
Steffen T. Simon
18University of Cologne, Faculty of Medicine and University Hospital, Department of Palliative Medicine and Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf (CIO ABCD), Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomy Tonia
19Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristoffer Marsaa
20Department of Multidisease, Nordsjaellands Hospital, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristoffer Marsaa
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

There is increased awareness of palliative care needs in people with COPD or interstitial lung disease (ILD). This European Respiratory Society (ERS) task force aimed to provide recommendations for initiation and integration of palliative care into the respiratory care of adult people with COPD or ILD.

The ERS task force consisted of 20 members, including representatives of people with COPD or ILD and informal caregivers. Eight questions were formulated, four in the Population, Intervention, Comparison, Outcome format. These were addressed with full systematic reviews and application of Grading of Recommendations Assessment, Development and Evaluation for assessing the evidence. Four additional questions were addressed narratively. An “evidence-to-decision” framework was used to formulate recommendations.

The following definition of palliative care for people with COPD or ILD was agreed. A holistic and multidisciplinary person-centred approach aiming to control symptoms and improve quality of life of people with serious health-related suffering because of COPD or ILD, and to support their informal caregivers. Recommendations were made regarding people with COPD or ILD and their informal caregivers: to consider palliative care when physical, psychological, social or existential needs are identified through holistic needs assessment; to offer palliative care interventions, including support for informal caregivers, in accordance with such needs; to offer advance care planning in accordance with preferences; and to integrate palliative care into routine COPD and ILD care. Recommendations should be reconsidered as new evidence becomes available.

Tweetable abstract

The ERS task force recommends to consider offering palliative care, including advance care planning, to people with COPD or ILD and their informal caregivers when needs are identified, according to these needs, integrated into routine COPD and ILD care https://bit.ly/45E0IJu

Introduction

Chronic lung diseases are major causes of long-term disability and premature mortality worldwide [1, 2]. COPD is a leading cause of death and is predicted to be the fourth cause of death worldwide in 2030 [1, 3]. Although interstitial lung disease (ILD) is less prevalent than COPD, idiopathic pulmonary fibrosis as an example is associated with high symptom burden, reduced quality of life and short survival [4, 5]. The present guideline focuses on people with COPD and ILD with serious illnesses, defined as carrying a high risk of death, a negative impact on quality of life and functioning in life roles, and is burdensome in symptoms or caregiver stress [6]. People affected have palliative care needs in physical, psychological, social and spiritual/existential domains, equal to or greater than people with cancer [5, 7–11]. Informal caregivers (any relative, partner, friend, neighbour or significant other with personal relationship with the person cared for and who provides a broad range of unpaid assistance to the person with COPD or ILD [12]) have a major and complex role. They fulfil many tasks (supplementary material S1) [13–19], and are therefore the main, although often “hidden”, workforce responsible for providing most of the daily care [20]. Nevertheless, they generally receive insufficient support [13–16, 21]. A recent systematic review showed that palliative care interventions offered to people with nonmalignant diseases resulted in lower symptom burden, fewer visits to the emergency department and fewer hospitalisations [22]. Despite the mentioned benefits, people with COPD or ILD typically do not have access to the palliative care available to people with cancer [23, 24]. Disease trajectories of people with serious COPD or ILD are highly individual and difficult to predict [25, 26]. In COPD, only one third of deaths are due to a pulmonary cause; approximately a quarter are due to a cardiovascular cause and approximately a fifth are due to cancer [27]. In contrast, ILD is a diverse group of respiratory illnesses associated with different likelihoods of survival [26]. This uncertain prognosis, confusion with end-of-life care and not knowing when to initiate palliative care are barriers towards palliative care [23, 28]. The death of people with COPD or ILD is often perceived as unexpected and they are less likely to die at home than people with cancer [29–31], which may affect the bereavement experience [32, 33].

Despite inclusion in disease-specific guidelines and some national statements [34–37], a European clinical practice guideline on palliative care for people with chronic lung diseases is lacking. Therefore, the European Respiratory Society (ERS) task force for palliative care aimed to provide recommendations for initiation and integration of palliative care for adult people with COPD or ILD and their informal caregivers. Our objectives were to raise awareness and assess the effectiveness of palliative care, provide a clinician guide to palliative care implementation and identify knowledge gaps to inform future research. The present guideline is not limited to hospice care, which often refers to care for the dying or a location of care in the community [38]. Although for some people “supportive care” has a more positive association than “palliative care”, we use the term palliative care, while a well-accepted definition for supportive care is lacking. Moreover, supportive care is sometimes viewed as a component of oncology [39].

Methods

We used ERS methodology for clinical practice guideline development [40, 41] (supplementary figure S1 and supplementary material). Co-chaired by D.J.A. Janssen and K. Marsaa, the multidisciplinary ERS task force consisted of 20 members, including three representatives of people with COPD or ILD and informal caregivers, and specialists in nursing, respiratory medicine, palliative care, primary care, internal medicine, medicine for older people, pulmonary rehabilitation, physiotherapy, psychology and methodology. Conflicts of interest were declared and managed according to ERS policies. Representatives of people with COPD or ILD and informal caregivers actively participated in the discussions. One of the co-chairs (K. Marsaa) held two additional meetings with these representatives: one at the start of the process to discuss the aims of the task force and expectations and one to discuss their input for formulating recommendations. Following their input, the task force uses “person” with illness instead of “patient” where possible. The senior ERS methodologist (T. Thonia) supervised and ensured that all ERS methodological requirements were met, but did not participate in the formulation of questions or recommendations. An information specialist (S. Greenley) provided search expertise for all questions. Subgroups of four panellists were formed to work on each question, and the task force held monthly video conferences between November 2020 and September 2022.

Formulation of questions and outcomes

Panellists rated 14 potential topics for inclusion in the clinical practice guideline on a five-point Likert scale using an online survey (Qualtrics, Provo, UT, USA) to identify the most relevant clinical questions on palliative care for people with COPD or ILD. During three meetings, four questions using the PICO framework were defined as well as four complementary narrative questions [41] (table 1 and supplementary material S1). Each group member then voted, anonymously, on the importance of outcomes of interest for each Population, Intervention, Comparison, Outcome (PICO) question, using an online survey and a scoring system of 0 to 9 (1–3: not important; 4–6: important; 7–9: critical for clinical decision-making) following Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance [42]. Scores for each outcome were averaged and presented, and those scored as important or critical further discussed during one meeting until group consensus was reached for the final classification of the importance of outcomes [42] (supplementary material S1). Due to the large number of outcomes, only those deemed as critically important (scoring 7–9) were included.

View this table:
  • View inline
  • View popup
TABLE 1

Summary of European Respiratory Society task force questions and recommendations

Literature searches

For each question, a search strategy was designed and executed by the information specialist. Supplementary material S2 summarises the search process and presents full search strategies for all databases. Initial searches were conducted between February and May 2021 and updated 19–22 April 2022. A standard set of databases were searched for each question: MEDLINE (OVID), Embase (OVID), the Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials (the Cochrane Library), CINAHL (EBSCOhost), Scopus, Web of Science Core Collection and Epistemonikos with supplementary searches for systematic reviews undertaken in the online CareSearch systematic review collection resource. Search results were screened independently by two panellists for eligibility (refer to supplementary material S1 for inclusion/exclusion criteria). First, systematic reviews were screened. Systematic reviews that provided evidence for at least one of the outcomes of interest for one of the questions were used as a basis to add later studies. If no relevant systematic review was identified for a question, original studies were screened for inclusion. Whenever there were randomised controlled trials (RCTs) available, those were used as the main body of evidence. Relevant articles not included in the initial search could be added by the task force members. For each question, a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram documented the number of studies included and excluded at each step of screening [43]. For narrative questions seven and eight, task force members identified systematic reviews that had comparable aims and objectives to the questions and extracted relevant themes. Then, primary papers were identified that were relevant, but not included in the systematic reviews, and these were classified as either adding novel insights not identified in the systematic reviews, or corroborating existing themes.

Evidence syntheses and assessment of the quality of evidence

The literature review and the evidence profile tables for PICO questions three and four were performed by the University of Liège (Epidémiologie et Economie de la Santé). A recipient of the ERS Fellowship in Guideline Methodology with expertise in Public Health (M.H. Boon) conducted the systematic reviews, evidence syntheses and GRADE assessment for PICO questions five and six. Data from included studies for PICO questions three and four were extracted by one panellist and checked by another. Data from included studies for PICO question five and six were extracted by one panellist and checked by two others. Risk of bias was assessed by one panellist and discussed and agreed with two others. Risk of bias was assessed using the Cochrane Risk of Bias tool (version 1) for RCTs and Joanna Briggs Institute (JBI) tools for observational studies. Meta-analysis was not possible for any of the PICO questions, because of the limited evidence available. GRADE evidence profiles were created for each PICO question using the GRADEpro Guideline Development Tool (https://www.gradepro.org/), and the certainty of evidence was assessed based on the GRADE principles: risk of bias, indirectness, inconsistency, imprecision and publication bias [44, 45]. The GRADE evidence profiles were based on RCTs only, except for question six, for which the only included study had an observational design. The final certainty of outcomes for each question was rated as high, moderate, low or very low [46].

Formulating recommendations

For all questions, the evidence-to-decision framework was used to structure the discussions and to document the different factors considered for the recommendations [47, 48]. Apart from the evidence and its certainty, other factors considered in this framework included values and preferences of people with illness, resources, feasibility, health equity and acceptability. Draft recommendations were discussed with the task force until consensus was reached. One of the task force chairs (K. Marsaa), held an additional meeting with representatives of people with COPD or ILD and informal caregivers, and a representative from the European Lung Foundation, to discuss in depth their values and preferences concerning each question. Based on GRADE, the strength of the recommendations was rated as either strong (phrased “we recommend”) or conditional (phrased “we suggest”) [49, 50].

For the narrative questions, evidence was reviewed narratively to develop recommendations. For question one (definition), data were extracted for each study concerning what, what for, to whom, by which means, by whom, where, when and conditional requirements (supplementary material S3, adapted from Meyer et al. [51]). For question two (when to start), the framework of Philip et al. [52] was used to extract data on referral criteria. For questions seven and eight (implementation), a whole-systems approach was used as a framework for analysis [53], relating the findings of included papers to the needs of people with COPD or ILD, professional requirements and service organisation. Findings were then synthesised in a summary text and key themes illustrated in a schema. For all narrative questions, recommendations for research were drafted by the subgroup and discussed within the task force until consensus was reached.

Results

The number of studies identified and selected is shown in PRISMA diagrams for each question in supplementary figures S2 to S8. The evidence profile tables and evidence-to-decision frameworks are shown in supplementary material S3 (questions 1–6), S4 (questions 7 and 8 (COPD)) and S5 (questions 7 and 8 (ILD)). Recommendations are listed in table 1. Table 2 shows recommendations for research.

View this table:
  • View inline
  • View popup
TABLE 2

Recommendations for research

Question 1: how do we define palliative care for people with COPD or ILD? (narrative)

Recommendation

We suggest using the definition for palliative care for people with serious illness due to COPD or ILD as shown in box 1. (Conditional recommendation for the suggested definition: very low quality of evidence.)

View this table:
  • View inline
  • View popup
BOX 1

Definition of palliative care for people with COPD or interstitial lung disease (ILD)

Justification

A conditional recommendation was selected based upon the large agreement in the literature on the overall concept of palliative care across the included studies [54–58].

Summary of main findings

Results included three systematic reviews [54–56], a consensus Delphi study guideline [58] and a study using a summary content analysis, environmental scan and rapid review [57] (supplementary material S3). Studies reported that palliative care is a multidisciplinary approach offered to people with illness as well as their family and aiming to improve quality of life. Palliative care is offered in all settings where a person may have a serious illness and needs.

Other considerations

In a draft definition based on the extracted findings, a definition of specialist palliative care was missing. Therefore, an additional study was sought to define “specialist palliative care”. This study used a Delphi procedure and concluded that “specialist palliative care is offered by clinicians who have advanced knowledge of identifying dying, skills to assess and manage complex symptoms to improve quality of life, have advanced communication skills and perform distinct clinical practices (e.g. working with the whole family as the unit of care and providing support in complex bereavement)” [59]. For the current definition we have combined these skills into: “advanced knowledge of and training in palliative care”. ACP is included in the definition and is seen as “the ability to enable individuals to define goals and preferences for future medical treatment and care, to discuss these goals and preferences with family and healthcare providers, and to record and review these preferences if appropriate” [60]. Communication should be both effective (including that what is communicated is received and understood) as well as sensitive (titrated to the needs of the person with COPD or ILD and informal caregiver). Currently, social equity is not included in the identified definitions of palliative care.

Question 2: when to start a palliative care approach in COPD and ILD? (narrative)

Recommendation

We suggest that a palliative care approach should be considered when people with COPD or ILD and their informal caregivers have physical, psychological, social or spiritual/existential unmet needs. Needs should be actively sought by asking the person with illness or their informal caregiver, but surrogate markers of disease severity and/or health service utilisation may help identify those likely to have needs. (Conditional recommendation: low quality of evidence.)

Justification

Although the evidence level is low, a conditional recommendation was selected that palliative care should start when an unmet need arises [52, 61–68].

Summary of main findings

The search retrieved one systematic review [52], one observational study [61] and seven qualitative studies [62–68]. Multiple factors can contribute to late palliative care referral and inequitable variation in care. These include the unpredictable course of chronic respiratory disease, personal views of palliative care, and under-recognition of symptoms and concerns [69]. More standardised criteria for when to start a palliative care approach in COPD and ILD would enhance decision-making and consistency in practice. Available studies describe a range of criteria for when to start palliative care, based on either needs or markers of disease severity and/or health service utilisation review [52]. Referral criteria for palliative care in advanced COPD and ILD across the literature (62 articles: 52 COPD, four ILD, six mixed) are shown in table 3. The common criteria for starting palliative care include, in order of reporting: hospital use, respiratory status, physical or emotional symptoms, functional decline, use of advanced respiratory therapies, and disease progression [52]. Needs-based criteria function similarly across all diagnoses and can be elicited by asking the person with illness or informal caregiver, or in some cases using objective testing. However, their routine use requires clinicians to identify, assess and then respond to needs [68]. Disease-based criteria, e.g. hospital admissions, are often measured in health systems, but their relationship to unmet need is dependent on the disease and service delivery context. For example, a new diagnosis of idiopathic pulmonary fibrosis has been suggested as an appropriate time to start palliative care, yet starting palliative care following a diagnosis of mild COPD may raise undue concern among people with COPD and their families about expected speed of progression [66].

View this table:
  • View inline
  • View popup
TABLE 3

Categories of palliative care referral criteria across literature for people with serious illness due to COPD or interstitial lung disease (ILD) (with examples) [52, 62]

Other considerations

People with illness and informal caregivers are generally more willing to talk about current needs than potential future ones. They see consultations as about treating the “here and now”, but would like clinicians to initiate discussions about future care [65]. A structured question guide can help the person with illness to bring up symptoms and concerns which they consider “normal” limitations of disease or which they do not feel can be addressed [63]. Support groups can also help increase readiness for palliative care referral [61]. In primary care, practitioners use verbal and nonverbal indications from people with illness, informal caregivers and health records to identify when to start a palliative care approach. However, without formal screening, recognition of needs may occur late in the disease trajectory by which time it is severe [64]. Most needs will not require specialist palliative care, but potential for benefit depends on the skill-mix and competencies of the care team and delivery structure. The wide range of criteria demonstrates that there is no consensus for when to start a palliative care approach.

Question 3: in people with COPD and their informal caregivers, should palliative care interventions involving informal caregivers be used? (PICO)

Recommendation

In people with COPD, we suggest that palliative care interventions including support for informal caregivers should be offered. (Conditional recommendation: very low quality of evidence.)

Justification

In RCTs, palliative care interventions involving caregivers improved the quality of life and wellbeing [71–75] of people with COPD. Nevertheless, studies were highly heterogeneous, were often applied to mixed populations (not exclusively composed of people with COPD) [71, 74, 76, 77] and the involvement of and support provided to informal caregivers varied. Serious to very serious limitations were found in the GRADE evaluation.

Summary of main findings

28 studies [68, 71–95] were included, nine of which were RCTs [71–77, 82, 96]. In RCTs, palliative care interventions involving informal caregivers improved quality of life and wellbeing of people with COPD [71–75], but did not change symptoms of breathlessness [73, 74], anxiety or depression [72–75, 96]. Outcomes in informal caregivers were not assessed in these studies. Hence, the overall quality of evidence was considered very low for all outcomes.

Other considerations

Additional evidence from non-RCTs has shown that palliative care interventions involving informal caregivers: increased satisfaction with care among people with COPD and informal caregivers with care [76, 77, 85, 86, 90, 91, 97], enhanced quality of communication [97], raised awareness of proactive care for and involvement of informal caregivers [78], decreased symptoms in people with COPD [81, 89], increased confidence in managing symptoms [91, 92, 97] and reduced the mean number of respiratory emergency department visits [76, 98]. There was no evidence of undesirable effects. Strategies such as promoting more involvement of healthcare professionals in identifying eligible candidates for palliative care interventions, initiatives with patients’ associations, additional information via technology and peer support, might be needed to facilitate involvement of informal caregivers during the implementation of these interventions to real-world settings, according to the available resources.

Question 4: in people with ILD and their informal caregivers, should palliative care interventions involving informal caregivers be used? (PICO)

Recommendation

In people with ILD, we suggest that palliative care interventions including support for informal caregivers should be offered. (Conditional recommendation: very low quality of evidence.)

Justification

The number of available studies is very low; some outcomes of interest were never reported; and different instruments have been used to assess the outcomes of interest, leading to very low evidence regarding the use of palliative care interventions involving informal caregivers among people with ILD. Despite this, anxiety and quality of life of people with ILD and burden and depression of informal caregivers was shown to improve with palliative care interventions [99–101]. No serious to very serious limitations were found in the GRADE evaluation.

Summary of main findings

11 studies were included [85, 88, 95, 99–106], three of which were RCTs [99–101]. RCTs with palliative care interventions were few and very heterogeneous, often applied to mixed populations (not exclusively people with ILD) and the support offered to informal caregivers varied and included, for example, telephone contact with a specialised nurse, group sessions, nurse-led support groups or a booklet to address palliative care needs. Nevertheless, anxiety and quality of life of people with ILD and burden/stress and depression of informal caregivers were found to improve. No harmful or adverse events were reported with any of the interventions [99–101].

Other considerations

Additional evidence from non-RCTs found significant improvements in communication and discussions between people with ILD, informal caregivers and healthcare professionals after palliative care interventions [85, 102, 103, 106]. Such improvements enabled people with ILD to feel less isolated [100], have better symptom management [102, 104] and, in line with their preferences, were less likely to die in hospital [102, 106]. Informal caregivers felt better informed, more prepared, confident and better supported [101, 104, 106]. Satisfaction with care and its acceptability was generally high [99–101], and wishes for earlier access to interventions were expressed. We suggest informal caregivers are involved as early as possible in palliative care interventions implemented in different settings (home, community, hospitals) according to needs and preferences. Strategies such as promoting more involvement of healthcare professionals in identifying people eligible for palliative care interventions, availability of assessment tools, awareness sessions, initiatives with patients’ associations, educational programmes, and additional information via technology and peer support, might be needed to facilitate the involvement of informal caregivers during the implementation of these interventions in real-world settings, according to the available resources.

Question 5: in people with COPD, should advance care planning interventions be used? (PICO)

Recommendation

We suggest that advance care planning (ACP) should be offered to people with COPD. (Conditional recommendation: low quality of evidence.)

Remark: ACP should be periodically revised, respecting individual needs and values of people with COPD and their informal caregivers.

Justification

Evidence was limited, but demonstrated beneficial effects of ACP for people with COPD as improving quality of communication with healthcare professionals, increasing follow-up ACP discussions, and decreasing anxiety in informal caregivers [107]. Undesirable effects have not been systematically investigated, but they are considered small and mostly associated with healthcare professionals poorly skilled in ACP undertaking these discussions. The overall quality of evidence was considered as low.

Summary of main findings

Only one study met the eligibility criteria. The selected RCT [107] found that a nurse-led ACP intervention improved the quality of end-of-life care communication between people with COPD and their physicians, without causing psychosocial distress in either the person with COPD or the informal caregivers. In addition, the intervention increased the frequency of ACP discussions over the subsequent 6 months.

Other considerations (see also the section in questions 7 and 8 for evidence on implementation)

Nurse-led facilitated ACP is acceptable to people with advanced respiratory disease and is effective in increasing ACP discussions and completion of advance directives. Awareness of symptom burden, readiness to engage in ACP and relevant psychosocial factors may facilitate effective tailoring of ACP interventions and achieve greater uptake [108]. Challenges are how and when ACP should be implemented for people with COPD. The unpredictable trajectory of the disease and the varying readiness of the person with COPD are challenges, but also underline the need for timely ACP [109]. Sociocultural factors may play a role in how and when ACP discussions should be conducted. Nevertheless, lack of awareness of culture, religion and spirituality is experienced as a barrier towards ACP discussions with patients with chronic lung diseases [110]. Standardised ACP programmes (e.g. service guidelines and documentation) may facilitate the initiation and ongoing assessment of the plan, but should allow flexibility, respecting personal values and preferences. Healthcare professionals should be trained to conduct ACP discussions including how to address sociocultural factors (such as religion, beliefs and values). Undesirable effects have not been systematically investigated, but mostly appear to be related to poor healthcare professionals’ skills in conducting such discussions. As knowledge is still emerging in this area, studies regarding the effects of ACP in people with COPD and their informal caregivers are necessary.

Question 6: in people with ILD, should ACP interventions be used? (PICO)

Recommendation

We suggest that ACP should be offered to people with ILD. (Conditional recommendation: very low quality of evidence.)

Remark: ACP should be periodically revised, respecting individual needs and values of people with ILD and their informal caregivers.

Justification

There is limited evidence that ACP may decrease dying in hospital [102]. We consider it likely that the improved quality of communication seen with ACP in COPD would also be seen in people with ILD. Undesirable effects of ACP have not been systematically investigated, but no major concerns have been reported. The included study was an observational study with serious risk of bias and indirectness, so the overall quality of evidence was considered very low.

Summary of main findings

Only one study met the inclusion criteria [102]. In the selected study, a greater percentage of people with ILD who received ACP died at home or hospice compared to those who did not receive ACP [102].

Other considerations

Two additional studies that considered ACP in people with ILD did not meet the inclusion criteria, as they investigated ACP as part of a palliative care complex intervention and the independent effect of ACP could not be disaggregated from results. Qualitative data from one of these studies [99] suggested that people with ILD valued the formal ACP process as it allowed them to have important conversations that might not have otherwise been possible. The second study evaluated an ILD disease management programme that included ACP. The quantitative data from this study suggested decreased quality of life and increased anxiety in the intervention group, but these were not supported by the qualitative results. Qualitative data suggested that people with ILD felt less isolated following ACP discussion [100]. The willingness of people with ILD and informal caregivers to partake of ACP may increase over time [99]. There is limited evidence about how and when ACP should be implemented and any undesirable effects. Sociocultural factors may play a role in how and when ACP discussions should be conducted. Acceptability probably varies across different cultures and religions. As evidence is limited in this area, studies regarding the effects of ACP in people with ILD and their informal caregivers are necessary.

Questions 7 and 8: how do we implement palliative care and ACP with routine clinical care for people with COPD and ILD and their informal caregivers? (narrative)

Note: It became clear that it was not appropriate to separate implementation of palliative care and implementation of ACP because ACP was generally considered as a core component of palliative care and there was considerable overlap in articles. Therefore, we have combined the findings of the two searches. See supplementary material S4 and S5 for further details.

Recommendations

We suggest, with regard to people with COPD or ILD and their informal caregivers, services should:

  • 1) integrate palliative care into routine care, explicitly recognising active disease management and palliative care as complementary;

  • 2) provide accessible, multidisciplinary holistic assessment of physical, psychological, social and spiritual/existential needs;

  • 3) embed a system within an extended multidisciplinary team where people with COPD or ILD and persistent, unmet palliative care needs have access to specialist palliative care support;

  • 4) foster relationships with trusted healthcare professionals enabling continuity of care;

  • 5) recognise that initiating ACP conversations is challenging and should include analysis of context and timing to offer it. In addition, multidisciplinary services should prioritise training, clarify responsibilities and ensure capacity to offer timely ACP, with preferences checked as circumstances change.

(Conditional recommendation: low quality of evidence.)

Justification

While the lack of rigorous implementation trials mean that the certainty of evidence may be considered as “low”, there is consistency in findings across multiple studies with a broad range of methodologies. Our recommendations build on the key emerging themes from this narrative synthesis.

Summary of main findings

Our COPD evidence-base for this question represents data from 221 original studies (13 systematic reviews reporting 175 original papers, plus 46 primary studies not included in the systematic reviews). The ILD evidence-base represents data from 56 primary studies (four systematic reviews reporting 46 original papers, plus 10 primary studies not included in the systematic reviews). Refer to supplementary material S4 (COPD) and supplementary material S5 (ILD) for detailed synthesis of findings. In this summary, we have only included references to the systematic reviews and primary papers with novel findings.

The findings for COPD and ILD are illustrated in figure 1, and key themes of initiating palliative care, holistic needs assessment, integration with respiratory management, communication and ACP are described for each condition. In each theme we first describe the findings for people with COPD (which has the more mature literature) and then contrast with the findings for those with ILD. Key priorities for implementation of palliative care in terms of people with COPD and ILD, healthcare professionals and organisations are shown in tables 4 and 5. These are categorised in terms of people with COPD, healthcare professionals and organisations, a whole-systems framework used by five of the systematic reviews in COPD [68, 111, 112, 115, 116].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Schema of components of palliative care services for COPD or interstitial lung disease (ILD). This schema illustrates the consistent themes from the narrative synthesis (questions 7 and 8). From the left, a range of triggers can help identify people with COPD or ILD who would benefit from a palliative care approach, although there are barriers to be overcome. A standardised, multidisciplinary assessment is the entry point to the palliative care service and an essential prerequisite to planning appropriate care. The components of a palliative care service are classified as relating to the needs and preferences of the person with COPD or ILD and their informal caregiver, the skills and attributes of the healthcare professional, and the organisational considerations. Relief of suffering is the core aim and requires overlap of these three aspects of a palliative care service illustrated as the overlap of the coloured boxes representing components. Communication (between person with COPD or ILD/informal caregiver and healthcare professional, as well as between different professional groups) is a central theme and is illustrated underpinning the whole process. Advance care planning (ACP) is a key manifestation of the communication between the person with COPD or ILD and their informal caregiver, and the healthcare professional and thus illustrated emerging from the overlap of these two components. LTOT: long-term oxygen therapy; CRD: chronic respiratory disease.

View this table:
  • View inline
  • View popup
TABLE 4

Priorities for implementation of palliative care according to people with COPD, healthcare professionals and organisations

View this table:
  • View inline
  • View popup
TABLE 5

Priorities for implementation of palliative care according to people with interstitial lung disease (ILD), healthcare professionals and organisations

Theme 1: initiating a palliative care approach, or referral for palliative care services

Although indicators (e.g. hospitalisation, long-term oxygen therapy, symptom burden) can prompt referral of people with COPD to palliative care services [111, 112, 113, 115], some healthcare professionals hesitate to consider a palliative care approach [111, 112] due to the uncertain disease trajectory [111–113, 115, 119], lack of a clear transition to “end of life” [112, 114], normalisation of living with COPD [115] and lack of professional awareness of the potential role of palliative care [68, 115]. This is compounded by some people's reluctance to accept a referral to palliative care because of a misunderstood association with cancer and end of life [66, 68, 115], although once referred, acceptability is high [111]. There is limited evidence about optimal timing of referral [115], but “early” referral has been recommended [112, 113], defined in one study as when the severity of COPD is classified as “moderate” [66]. Some studies have proactively initiated screening (e.g. during a hospitalisation [111, 129]), or searching for prognostic indicators in primary care records [85, 111].

Similarly, people with ILD are often not referred to palliative care services, or referred too late to address the high levels of unmet need (e.g. 71% within the last month of life [126]). Suggested triggers for palliative care referral in ILD include oxygen therapy, ventilatory support, uncontrolled symptoms, functional decline and opioid consideration [102, 123, 124, 126, 130] as well as holistic needs (anxiety and depression, loneliness and isolation, and increasing informal caregiver dependence/burden) [102, 103, 124, 125, 128] (table 3). The poor prognosis and downward trajectory over time, albeit still seen as uncertain [123, 130], led to calls for a palliative care approach to be incorporated within usual care from soon after diagnosis [102, 103, 123, 128].

Theme 2: holistic needs assessment

Holistic assessment of needs (of people with COPD and informal caregivers [113]), is widely described as a crucial first step [68, 111, 113, 115, 116, 117], with practical advice that arrangements should be comprehensive [112, 116], accessible (including home visits) [111], interdisciplinary [116] and coordinated to avoid duplication between support agencies [120]. A multidimensional assessment should not only consider the needs of the person with COPD, informal caregivers and family, but also the timing of support [116, 121]. The validated Support Needs Approach for Patients tool asks people with advanced COPD to identify their support needs [131], but is not yet evaluated clinically. Another available tool is the Integrated Palliative Care Outcome Scale (IPOS) [132] to assess physical and emotional symptoms and communication/practical issues. IPOS is used in COPD across diverse settings and is suggested to be valid, reliable and responsive to change [132].

Similarly, for people with ILD, multidisciplinary, holistic needs assessment is preferable to a prognosis-based approach [102, 103, 123, 124, 125], with care plans and goals discussed while ambulatory rather than during an acute crisis. Three systematic approaches are described in the literature: a validated needs assessment tool to guide consultations (NAT-ILD) [125], a bespoke clinician supportive care decision aid [103], and a multidisciplinary collaborative ILD-palliative care bundle [102]. IPOS can also be used in people with ILD [132].

Theme 3: integrating palliative care with respiratory management

Several studies in COPD addressed service models in which palliative care was integrated into routine care [68, 111, 114, 120, 121, 122]. This approach recognises disease-modifying management and palliative care as complementary [114, 117], and facilitates early discussions of prognosis, ACP and holistic care [66]. Strategies to promote integration include joint respiratory/palliative care clinics [85], providing respiratory clinicians with palliative care skills [68], regular interprofessional communication [112, 120] and involvement of a key professional to coordinate multidisciplinary working and information transfer between sectors [114, 117, 122]. Raising awareness among professionals and the public was important [113, 115], normalising a palliative care approach [121]. Healthcare policy enables these initiatives by supporting organisational change and re-alignment of services [115, 118, 133].

A needs-based approach was similarly recommended for people with ILD [102, 103, 123, 124, 125], with care coordinated across primary, respiratory (including pulmonary rehabilitation) and specialist palliative care settings, with adequate allied health support to enable care at home (if preferred) [102, 103, 123, 124, 128]. Palliative care should be part of multidisciplinary case discussion and a palliative approach triggered by unmet needs, and not seen as a “near-death” intervention [102, 103, 123, 124, 125, 128]. Ongoing specialist palliative care for every person with ILD is unnecessary and unsustainable [103, 127], but needs should be identified systematically to ensure appropriate expertise is involved. Holistic needs assessment involves using an assessment tool and clinical conversation [103, 125, 127], preferably in the ambulatory care setting and not during an acute admission [103, 125, 127], and in consideration of caregivers’ needs [102, 123, 124, 125].

Theme 4: communication

Communication was a key theme not only among people with COPD and informal caregivers, but also among healthcare professionals. Strategies to overcome fragmented services [134], included allocating an accessible, named professional able to signpost resources [78, 111, 120, 122], regular multidisciplinary team meetings [116, 120], joint consultations [85] and case management [113]. Most people with COPD value open and honest communication about their prognosis [78, 97, 112, 115, 118, 122]. Digital communication may be useful including phone calls [135], telemonitoring [111], teleconsultations [136] and web-based counselling or support for ACP [113].

Good communication was also emphasised as crucial for people with ILD. Poor communication between sectors and teams was seen as a major obstacle [124, 126, 130]. Inappropriate optimism, perpetuated by poor communication skills and/or confidence was a problem, as healthcare professionals avoided talking about goals of care for fear of “taking away hope” [124, 126, 137]. The concept of palliative care providing a layer of care alongside active treatment was not commonly understood [123, 124, 126], and often referrals were seen as a covert message that death was very near [123, 124].

Theme 5: ACP

ACP was uniformly described as central to a palliative care approach in both COPD and ILD [113, 115]. Decisions regarding preferences for end-of-life management in COPD (e.g. ventilation, resuscitation) were influenced by the individual's prognostic awareness, illness burden and existential concerns [138]. Systematic ACP provision for people with COPD improved involvement in decision-making [111, 112], and recording of their wishes [134], with the caveat that pre-stated wishes could change [139], and were not always respected [121, 134]. ACP was perceived to be related to improved control, and confidence in self-managing symptoms [111, 112], but associated changes in unscheduled care and quality of life were variable [111, 140].

In the context of poor public understanding of COPD [141], people with COPD often lacked insight into their likely prognosis [65, 66], and informal caregivers were unprepared for the death [26]. A core function of ACP was to meet information needs [65, 113, 142, 143], recognising that the needs of people with COPD and informal caregivers may be different [78, 112, 113, 118]. A significant minority avoid discussion about prognosis [112, 113, 141, 143] and, even if they wanted information, rarely initiated the conversation [142]. Group sessions (e.g. within pulmonary rehabilitation) were perceived as less threatening than individual discussions, although a few found them “depressing” [139, 144].

Professionals acknowledge the importance of ACP but are unsure when, and how, to start the conversation. They were aware that some people with COPD avoid discussing prognosis, and are afraid of destroying hope by doing so [145]. Therefore, ACP conversations are rarely initiated by professionals [66, 109, 112, 114, 145], who prefer people with COPD to initiate the discussion [38], which rarely happens [142]. ACP discussions are best delivered by a trusted healthcare professional [65, 139, 141, 142, 145], with advanced communication skills [68, 112, 115] and trained in ACP [109, 112, 115, 117, 135, 141–143], optimally timed for the patient [135, 139, 141, 143, 145] and including informal carers if wished by the patient [146]. The legal context and place of advance directives was highlighted in one paper [147]. Organisational barriers to incorporating ACP into routine COPD care [109, 121], include lack of capacity [65, 142, 143, 145], and no clarity on who is responsible for initiating ACP [109, 141–143], or triggers (e.g. hospitalisation) that could indicate appropriate timing [65, 109, 143]. Offers of ACP discussions need to be repeated as preferences change [139, 141, 142]. Use of technology (e.g. a web-based ACP tool for lung disease) was potentially useful and acceptable [113].

The findings for COPD were mirrored in the ILD literature [126, 123, 124, 128]. Planning for palliative care at an early stage of the disease with a systematic approach to conversations about disease progression, improving communication about end-of-life needs help people with ILD and informal caregivers manage the uncertainty of illness.

Other considerations

Despite some differences (for example, in the duration of the disease trajectory), the challenges in initiating and delivering an integrated approach to supportive and palliative care for people with COPD and ILD share many features. We have illustrated the considerations for a model of care in a single schema (figure 1) with some differences highlighted. It is important to remember that the evidence base in COPD is far greater than in ILD, and some specific features of ILD care may not be represented in the currently available literature. Research is needed to inform service delivery, specifically implementation of models that integrate palliative care approach into routine care of people with COPD or ILD.

Discussion

The ERS task force evaluated eight questions, including four PICO questions and four narrative questions concerning palliative care for people with COPD or ILD, which were not addressed in previous international guidelines. This resulted in eight conditional recommendations (including a definition for palliative care for people with COPD or ILD), which were based on very low to low quality of evidence. Besides quality of evidence, people with illness and informal caregivers’ values and preferences, resources, feasibility, and acceptability were included into the considerations. In addition, recommendations for future research are provided.

Key findings

There was general agreement in literature that a definition of palliative care for people with serious illness due to COPD or ILD should include components such as a multidisciplinary and holistic approach; the aim to control symptoms and to improve quality of life; the need to support informal caregivers; and the need to provide palliative care in the place of choice. A needs-based approach is suggested to identify people with serious illness who may benefit from a palliative care approach. These include physical, psychological and social as well as spiritual/existential needs. This is in line with the view of the task force of the European Association for Palliative Care concerning initiation of palliative care in people with chronic heart failure [148]. Moreover, the recent official American Thoracic Society/American Academy of Hospice and Palliative Medicine/Hospice & Palliative Nurses Association/Social Work Hospice and Palliative Care Network policy statement Palliative Care Early in the Care Continuum Among Patients with Serious Respiratory Illness also recommends offering palliative care to people with serious respiratory illnesses using a needs-based approach [149].

Research is needed to explore markers of disease severity and health service utilisation related to palliative care needs and optimal ways to identify and respond to needs. In people with COPD or ILD, we suggest offering palliative care interventions that include support for informal caregivers. These recommendations were based on very low quality of evidence and, unfortunately, meta-analysis was not possible. However, it is important to realise that there was no evidence of undesirable effects of these palliative care interventions. Moreover, meta-analysis of palliative care interventions in a broader population of chronic nonmalignant diseases have shown positive effects on symptom burden, reduced emergency department visits and hospitalisations, but no association with quality of life, which was one of our critical outcomes [22]. A recent systematic review of palliative care interventions in COPD, not limited to those including family caregivers, suggested improved outcomes for people with COPD, but again a meta-analysis was not possible and effects were heterogeneous [111]. Studies are needed to establish the effects of palliative care interventions for people with COPD or ILD involving informal caregivers on critical outcomes such as communication, anxiety, depression, burden for informal caregivers and wellbeing of the person with illness as well as informal caregiver.

We suggest that ACP should be offered to people with COPD or ILD. However, in both illnesses only one study was selected from the literature, so meta-analyses were not possible. A meta-analysis of ACP in a broader population showed that ACP increased documentation of advance directives and discussions about end-of-life care, but did not include a meta-analysis concerning our other critical outcomes, like experience of end-of-life care, avoidable hospital visits near the end of life, or symptom control at the end of life [150]. Therefore, further research exploring effects of ACP offered to people with COPD or ILD on these outcomes is necessary. Additional research gaps include components of ACP, and cost-effectiveness.

Finally, a schema of components of palliative care services for COPD or ILD was drafted (figure 1), based on a narrative review of the literature about implementation of palliative care and ACP in routine COPD and ILD care. Our “whole systems” approach classified components as those that directly address the needs of the person with COPD or ILD, those that support or upskill the professionals, and organisational strategies that underpin the multidisciplinary service. Not all components will be relevant in all settings, but policy-makers and those developing services may wish to consider the components as a “pick list” that they can adopt/adapt to suit their context. Specific targets of future research should be clinical evaluation of holistic need assessment tools, interventions to overcome barriers towards ACP, and implementation of models that integrate a palliative care approach into routine care of people with COPD or ILD. There are regional/national/international differences in access to palliative care services [151, 152], which should be taken into account in studying models of palliative care.

Limitations

There are several limitations concerning the present clinical practice guideline. First, all recommendations are conditional and based on very low to low quality of evidence. Nevertheless, values and preferences of people with COPD or ILD and informal caregivers guided formulation of the recommendations in addition to the quality of the evidence. Second, we could only address eight questions, while the task force identified 14 potential topics for inclusion. Examples of topics that were not addressed and may be relevant for future clinical practice guidelines are symptom management such as palliative treatment of breathlessness, existential needs and bereavement support. Third, two PICO questions explicitly focused on palliative care interventions involving informal caregivers because of the agreement in the literature concerning the definition of palliative care, as well as agreement among the task force members (including representatives of people with COPD or ILD and informal caregivers). To this end, palliative care interventions not involving informal caregivers were not considered in question three and four of the current guideline, and thereby excluded significant literature regarding effectiveness of palliative care in this population. Importantly, we have sought to synthesise the literature on models of care to provide some insights into how innovative approaches can be implemented. Fourth, social equity was not included in the identified definitions of palliative care. Research among vulnerable people points out that inequity is present in access to palliative care [153, 154]. Surprisingly, social inequity wasn't found in the literature of questions 7 and 8. Therefore, this may be an important factor to consider in future studies and palliative care definitions. Fifth, in the present guideline, we interpreted ACP according to the definition of the European Association for Palliative Care [60]. Nevertheless, more definitions are available, and ACP can have different legal status around the world [155, 156]. Sixth, in the present guideline, we considered specialised as well as primary palliative care interventions. Although outcomes between these interventions might differ [157], we did not take this into account. Seventh, the literature on palliative care for people with ILD is limited. Therefore, at this moment it is not possible to provide separate recommendations for the diverse group of respiratory illnesses categorised as ILD. By recommending the needs approach instead of a disease-specific approach, we believe that palliative care can be adjusted to the personalised needs of people with ILD. Eighth, most committee members were palliative care experts from Western European countries. Therefore, perspectives of East and Southern European countries as well as perspectives from clinicians with limited expertise in palliative care were underrepresented.

Conclusion

The task force formulated eight conditional recommendations concerning the definition of palliative care for people with COPD or ILD, when to initiate a palliative care approach for people with COPD or ILD and their informal caregivers, palliative care interventions involving informal caregivers, ACP and the implementation of palliative care interventions and ACP integrated with routine COPD and ILD care. These recommendations were based on very low to low quality of evidence, the values and preferences of people with COPD or ILD and their informal caregivers, resources, feasibility and acceptability. However, given the consistency of the existing evidence, services should consider providing palliative care in line with these recommendations while awaiting further research. As new evidence becomes available, these recommendations should be reconsidered and the guideline updated.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary figures ERJ-02014-2022.supplementfigs

Supplement S1: PICO questions and outcomes with in- and exclusion criteria ERJ-02014-2022.supplement1

Supplement S2: Search strategy ERJ-02014-2022.supplement2

Supplement S3: Evidence summary tables and GRADE evidence profiles; Evidence to decision frameworks ERJ-02014-2022.supplement3

Supplement S4: Methods and findings for Q7 and 8 (COPD) ERJ-02014-2022.supplement4

Supplement S5: Methods and findings for Q7 and 8 (ILD) ERJ-02014-2022.supplement5

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02014-2022.Shareable

Acknowledgements

The task force members would like to thank Margaret Ogden for her input as a representative of people with chronic lung diseases in the early stages of this guideline.

Footnotes

  • This document was endorsed by the ERS Executive Committee on 25 May 2023.

  • A plain language summary of this document can be found at https://europeanlung.org/en/information-hub/factsheets/palliative-care/

  • The guidelines published by the European Respiratory Society (ERS) incorporate data obtained from a comprehensive and systematic literature review of the most recent studies available at the time. Health professionals are encouraged to take the guidelines into account in their clinical practice. However, the recommendations issued by this guideline may not be appropriate for use in all situations. It is the individual responsibility of health professionals to consult other sources of relevant information, to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary, and to verify rules and regulations applicable to drugs and devices at the time of prescription.

  • Conflict of interest: D.J.A. Janssen reports lecture fees from Boehringer Ingelheim (personal), Chiesi (non-personal), AstraZeneca (non-personal) and Abbott (non-personal) within the previous three years outside the submitted work.

  • Conflict of interest: C. Coleman is an employee of the European Lung Foundation.

  • Conflict of interest: D.C. Currow has received intellectual property payments and consultancy fees from Mayne Pharma International Pty Ltd, manufacturers of Kapanol and is a paid adviser to Helsinn Pharmaceuticals.

  • Conflict of interest: G.P. Kurita has received grants from Novo Nordisk Foundation, the Danish Cancer Society and European Commission outside the submitted work.

  • Conflict of interest: M. Maddocks is supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust; the views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

  • Conflict of interest: H. Pinnock has received speaker fees from Boehringer Ingelheim, Teva, and Sandoz for non-promotional talks on digital respiratory health and asthma supported selfmanagement.

  • Conflict of interest: T. Tonia is a methodologist for the European Respiratory Society.

  • Conflict of interest: K. Marsaa reports lecture fees from Astellas Pharma, GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, Kyowa Kirin, Norgine, Roche, Bristol-Myers Squibb, Chiesi Pharma outside the submitted work.

  • Conflict of interest: All other panellists have no conflicts of interest to report.

  • Support statement: This work was supported by the European Respiratory Society (grant: 2019-11). Funding information for this article has been deposited with the Crossref Funder Registry.

  • This article has an editorial commentary: https://doi.org/10.1183/13993003.01076-2023

  • Received October 17, 2022.
  • Accepted May 6, 2023.
  • Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. GBD 2017 Causes of Death Collaborators
    . Global, regional, and national age–sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736–1788. doi:10.1016/S0140-6736(18)32203-7
    OpenUrlCrossRefPubMed
  2. ↵
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators
    . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858. doi:10.1016/S0140-6736(18)32279-7
    OpenUrlCrossRefPubMed
  3. ↵
    1. Mathers CD,
    2. Loncar D
    . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442. doi:10.1371/journal.pmed.0030442
    OpenUrlCrossRefPubMed
  4. ↵
    1. Rajala K,
    2. Lehto JT,
    3. Sutinen E, et al.
    Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulm Med 2018; 18: 172. doi:10.1186/s12890-018-0738-x
    OpenUrlPubMed
  5. ↵
    1. Ahmadi Z,
    2. Wysham NG,
    3. Lundstrom S, et al.
    End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax 2016; 71: 510–516. doi:10.1136/thoraxjnl-2015-207439
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kelley AS
    . Defining ‘serious illness’. J Palliat Med 2014; 17: 985. doi:10.1089/jpm.2014.0164
    OpenUrlPubMed
  7. ↵
    1. Kreuter M,
    2. Bendstrup E,
    3. Russell AM, et al.
    Palliative care in interstitial lung disease: living well. Lancet Respir Med 2017; 5: 968–980. doi:10.1016/S2213-2600(17)30383-1
    OpenUrl
    1. Maddocks M,
    2. Lovell N,
    3. Booth S, et al.
    Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet 2017; 390: 988–1002. doi:10.1016/S0140-6736(17)32127-X
    OpenUrlPubMed
    1. Koyauchi T,
    2. Suzuki Y,
    3. Sato K, et al.
    Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax 2021; 76: 248–255. doi:10.1136/thoraxjnl-2020-215917
    OpenUrlAbstract/FREE Full Text
    1. Luckett T,
    2. San Martin A,
    3. Currow DC, et al.
    A systematic review and meta-analysis of studies comparing burden from lung cancer and chronic obstructive pulmonary disease. Palliat Med 2020; 34: 1291–1304. doi:10.1177/0269216320940153
    OpenUrl
  8. ↵
    1. Ahmadi Z,
    2. Lundström S,
    3. Janson C, et al.
    End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. Eur Respir J 2015; 46: 1190–1193. doi:10.1183/09031936.00035915
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Smith P
    . Who is a carer? Experiences of family caregivers in palliative care. In: Payne S, Ellis-Hill C, eds. Chronic and Terminal Illness: New Perspectives on Caring and Carers. Oxford, Oxford University Press, 2001; pp. 83–99.
  10. ↵
    1. Lippiett KA,
    2. Richardson A,
    3. Myall M, et al.
    Patients and informal caregivers’ experiences of burden of treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a systematic review and synthesis of qualitative research. BMJ Open 2019; 9: e020515. doi:10.1136/bmjopen-2017-020515
    OpenUrlAbstract/FREE Full Text
    1. Overgaard D,
    2. Kaldan G,
    3. Marsaa K, et al.
    The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J 2016; 47: 1472–1480. doi:10.1183/13993003.01566-2015
    OpenUrlAbstract/FREE Full Text
    1. Strang S,
    2. Osmanovic M,
    3. Hallberg C, et al.
    Family caregivers’ heavy and overloaded burden in advanced chronic obstructive pulmonary disease. J Palliat Med 2018; 21: 1768–1772. doi:10.1089/jpm.2018.0010
    OpenUrl
  11. ↵
    1. Marques A,
    2. Cruz J,
    3. Brooks D
    . Interventions to support informal caregivers of people with chronic obstructive pulmonary disease: a systematic literature review. Respiration 2021; 100: 1230–1242. doi:10.1159/000517032
    OpenUrl
    1. Dzingina MD,
    2. Reilly CC,
    3. Bausewein C, et al.
    Variations in the cost of formal and informal health care for patients with advanced chronic disease and refractory breathlessness: a cross-sectional secondary analysis. Palliat Med 2017; 31: 369–377. doi:10.1177/0269216317690994
    OpenUrlPubMed
    1. Shah RJ,
    2. Collard HR,
    3. Morisset J
    . Burden, resilience and coping in caregivers of patients with interstitial lung disease. Heart Lung 2018; 47: 264–268. doi:10.1016/j.hrtlng.2018.03.004
    OpenUrlPubMed
  12. ↵
    1. Bryant J,
    2. Mansfield E,
    3. Boyes AW, et al.
    Involvement of informal caregivers in supporting patients with COPD: a review of intervention studies. Int J Chron Obstruct Pulmon Dis 2016; 11: 1587–1596. doi:10.2147/COPD.S107571
    OpenUrl
  13. ↵
    1. Wolff JL,
    2. Spillman BC,
    3. Freedman VA, et al.
    A national profile of family and unpaid caregivers who assist older adults with health care activities. JAMA Intern Med 2016; 176: 372–379. doi:10.1001/jamainternmed.2015.7664
    OpenUrl
  14. ↵
    1. Currow DC,
    2. Farquhar M,
    3. Ward AM, et al.
    Caregivers’ perceived adequacy of support in end-stage lung disease: results of a population survey. BMC Pulm Med 2011; 11: 55. doi:10.1186/1471-2466-11-55
    OpenUrlCrossRefPubMed
  15. ↵
    1. Quinn KL,
    2. Shurrab M,
    3. Gitau K, et al.
    Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: a systematic review and meta-analysis. JAMA 2020; 324: 1439–1450. doi:10.1001/jama.2020.14205
    OpenUrlCrossRefPubMed
  16. ↵
    1. Gersten RA,
    2. Seth B,
    3. Arellano L, et al.
    Provider perspectives on and access to palliative care for patients with interstitial lung disease. Chest 2022; 162: 375–384. doi:10.1016/j.chest.2022.03.009
    OpenUrl
  17. ↵
    1. Strang P,
    2. Fürst P,
    3. Hedman C, et al.
    Chronic obstructive pulmonary disease and lung cancer: access to palliative care, emergency room visits and hospital deaths. BMC Pulm Med 2021; 21: 170. doi:10.1186/s12890-021-01533-3
    OpenUrl
  18. ↵
    1. Naya IP,
    2. Tombs L,
    3. Muellerova H, et al.
    Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res 2018; 19: 222. doi:10.1186/s12931-018-0928-3
    OpenUrl
  19. ↵
    1. Kolb M,
    2. Vašáková M
    . The natural history of progressive fibrosing interstitial lung diseases. Respir Res 2019; 20: 57. doi:10.1186/s12931-019-1022-1
    OpenUrlPubMed
  20. ↵
    1. Calverley PM,
    2. Anderson JA,
    3. Celli B, et al.
    Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789. doi:10.1056/NEJMoa063070
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Ngwenya N,
    2. Crang C,
    3. Farquhar M, et al.
    Communicating uncertainty: contrasting the communication experiences of patients with advanced COPD and incurable lung cancer. Fam Pract 2021; 38: 637–643. doi:10.1093/fampra/cmab024
    OpenUrl
  22. ↵
    1. Cohen J,
    2. Beernaert K,
    3. Van den Block L, et al.
    Differences in place of death between lung cancer and COPD patients: a 14-country study using death certificate data. NPJ Prim Care Respir Med 2017; 27: 14. doi:10.1038/s41533-017-0017-y
    OpenUrlPubMed
    1. Rajala K,
    2. Lehto JT,
    3. Saarinen M, et al.
    End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care 2016; 15: 85. doi:10.1186/s12904-016-0158-8
    OpenUrlPubMed
  23. ↵
    1. Butler SJ,
    2. Ellerton L,
    3. Gershon AS, et al.
    Comparison of end-of-life care in people with chronic obstructive pulmonary disease or lung cancer: a systematic review. Palliat Med 2020; 34: 1030–1043. doi:10.1177/0269216320929556
    OpenUrlCrossRefPubMed
  24. ↵
    1. Egerod I,
    2. Kaldan G,
    3. Shaker SB, et al.
    Spousal bereavement after fibrotic interstitial lung disease: a qualitative study. Respir Med 2019; 146: 129–136. doi:10.1016/j.rmed.2018.12.008
    OpenUrl
  25. ↵
    1. Hasson F,
    2. Spence A,
    3. Waldron M, et al.
    Experiences and needs of bereaved carers during palliative and end-of-life care for people with chronic obstructive pulmonary disease. J Palliat Care 2018; 25: 157–163. doi:10.1177/082585970902500302
    OpenUrl
  26. ↵
    1. Marsaa K,
    2. Gundestrup S,
    3. Jensen JU, et al.
    Danish Respiratory Society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. Eur Clin Respir J 2018; 5: 1530029. doi:10.1080/20018525.2018.1530029
    OpenUrl
    1. Pallialine
    . Richtlijn Palliatieve Zorg Bij Mensen Met COPD 2.0. 2021. www.pallialine.nl/copd. Date last accessed: 2 October 2022.
    1. National Institute for Health and Care Excellence (NICE)
    . Idiopathic Pulmonary Fibrosis in Adults: Diagnosis and Management. NICE Guideline CG163 (2013), Recommendation 1.5.10. 2015. www.nice.org.uk/guidance/qs79/chapter/quality-statement-5-palliative-care#source-guidance-5. Date last accessed: 1 June 2022.
  27. ↵
    1. National Institute for Health and Care Excellence (NICE)
    . Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. NICE Guideline [NG115]. Recommendations 1.2.106-110. 2019. www.nice.org.uk/guidance/ng115/chapter/Recommendations#multidisciplinary-management. Date last accessed: 1 June 2022.
  28. ↵
    1. Hawthorne DL,
    2. Yurkovich NJ
    . Hope at the end of life: making a case for hospice. Palliat Support Care 2004; 2: 415–417. doi:10.1017/S1478951504040544
    OpenUrlPubMed
  29. ↵
    1. Sobocki BK,
    2. Guziak M
    . The terms supportive and palliative care – analysis of their prevalence and use: quasi-systematic review. Palliat Med Pract 2021; 15: 248–253. DOI: 10.5603/PMPI.2021.0014
    OpenUrl
  30. ↵
    1. Nagavci B,
    2. Tonia T,
    3. Roche N, et al.
    European Respiratory Society clinical practice guidelines: methodological guidance. ERJ Open Res 2022; 8: 00655-2021. doi:10.1183/23120541.00655-2021
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Miravitlles M,
    2. Tonia T,
    3. Rigau D, et al.
    New era for European Respiratory Society clinical practice guidelines: joining efficiency and high methodological standards. Eur Respir J 2018; 51: 1800221. doi:10.1183/13993003.00221-2018
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Guyatt GH,
    2. Oxman AD,
    3. Kunz R, et al.
    GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395–400. doi:10.1016/j.jclinepi.2010.09.012
    OpenUrlCrossRefPubMed
  33. ↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al.
    The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. doi:10.1136/bmj.n71
    OpenUrlFREE Full Text
  34. ↵
    1. Guyatt G,
    2. Oxman AD,
    3. Akl EA, et al.
    GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383–394. doi:10.1016/j.jclinepi.2010.04.026
    OpenUrlCrossRefPubMed
  35. ↵
    1. Schünemann H,
    2. Brożek J,
    3. Guyatt G, et al.
    Chapter 5.1 Factors determining the quality of evidence. In: GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. The GRADE Working Group. 2013. https://gdt.gradepro.org/app/handbook/handbook.html
  36. ↵
    1. Guyatt G,
    2. Oxman AD,
    3. Sultan S, et al.
    GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 2013; 66: 151–157. doi:10.1016/j.jclinepi.2012.01.006
    OpenUrlCrossRefPubMed
  37. ↵
    1. Alonso-Coello P,
    2. Oxman AD,
    3. Moberg J, et al.
    GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016; 353: i2089. doi:10.1136/bmj.i2089
    OpenUrlFREE Full Text
  38. ↵
    1. Alonso-Coello P,
    2. Schünemann HJ,
    3. Moberg J, et al.
    GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 2016; 353: i2016. doi:10.1136/bmj.i2016
    OpenUrlFREE Full Text
  39. ↵
    1. Guyatt GH,
    2. Oxman AD,
    3. Vist GE, et al.
    GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926. doi:10.1136/bmj.39489.470347.AD
    OpenUrlFREE Full Text
  40. ↵
    1. Andrews J,
    2. Guyatt G,
    3. Oxman AD, et al.
    GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719–725. doi:10.1016/j.jclinepi.2012.03.013
    OpenUrlCrossRefPubMed
  41. ↵
    1. Meyer T,
    2. Kiekens C,
    3. Selb M, et al.
    Toward a new definition of rehabilitation for research purposes: a comparative analysis of current definitions. Eur J Phys Rehabil Med 2020; 56: 672–681. doi:10.23736/S1973-9087.20.06610-1
    OpenUrl
  42. ↵
    1. Philip J,
    2. Collins A,
    3. Smallwood N, et al.
    Referral criteria to palliative care for patients with respiratory disease: a systematic review. Eur Respir J 2021; 58: 2004307. doi:10.1183/13993003.04307-2020
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Kennedy A,
    2. Rogers A,
    3. Bower P
    . Support for self care for patients with chronic disease. BMJ 2007; 335: 968–970. doi:10.1136/bmj.39372.540903.94
    OpenUrlFREE Full Text
  44. ↵
    1. Bausewein C,
    2. Higginson IJ
    . Challenges in defining ‘palliative care’ for the purposes of clinical trials. Curr Opin Support Palliat Care 2012; 6: 471–482. doi:10.1097/SPC.0b013e32835998f5
    OpenUrlPubMed
    1. Hui D,
    2. De La Cruz M,
    3. Mori M, et al.
    Concepts and definitions for ‘supportive care,’ ‘best supportive care,’ ‘palliative care,’ and ‘hospice care’ in the published literature, dictionaries, and textbooks. Support Care Cancer 2013; 21: 659–685. doi:10.1007/s00520-012-1564-y
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Van Mechelen W,
    2. Aertgeerts B,
    3. De Ceulaer K, et al.
    Defining the palliative care patient: a systematic review. Palliat Med 2013; 27: 197–208. doi:10.1177/0269216311435268
    OpenUrlCrossRefPubMed
  46. ↵
    1. Xiao J,
    2. Brenneis C,
    3. Ibrahim N, et al.
    Definitions of palliative care terms: a consensus-oriented decision-making process. J Palliat Med 2021; 24: 1342–1350. doi:10.1089/jpm.2020.0679
    OpenUrl
  47. ↵
    1. Radbruch L,
    2. De Lima L,
    3. Knaul F, et al.
    Redefining palliative care – a new consensus-based definition. J Pain Symptom Manage 2020; 60: 754–764. doi:10.1016/j.jpainsymman.2020.04.027
    OpenUrlCrossRefPubMed
  48. ↵
    1. Forbat L,
    2. Johnston N,
    3. Mitchell I
    . Defining ‘specialist palliative care': findings from a Delphi study of clinicians. Aust Health Rev 2020; 44: 313–321. doi:10.1071/AH18198
    OpenUrl
  49. ↵
    1. Rietjens JAC,
    2. Sudore RL,
    3. Connolly M, et al.
    Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol 2017; 18: e543–e551. doi:10.1016/S1470-2045(17)30582-X
    OpenUrlCrossRefPubMed
  50. ↵
    1. Zou RH,
    2. Nouraie S,
    3. Rosenzweig MQ, et al.
    Evaluating the role of support group participation on palliative care referral and mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2023; 207: A4093. doi:10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4093
    OpenUrl
  51. ↵
    1. Iyer AS,
    2. Dionne-Odom JN,
    3. Khateeb DM, et al.
    A qualitative study of pulmonary and palliative care clinician perspectives on early palliative care in chronic obstructive pulmonary disease. J Palliat Med 2020; 23: 513–526. doi:10.1089/jpm.2019.0355
    OpenUrl
  52. ↵
    1. Kendall M,
    2. Buckingham S,
    3. Ferguson S, et al.
    Exploring the concept of need in people with very severe chronic obstructive pulmonary disease: a qualitative study. BMJ Support Palliat Care 2018; 8: 468–474. doi:10.1136/bmjspcare-2015-000904
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Claessen SJ,
    2. Francke AL,
    3. Engels Y, et al.
    How do GPs identify a need for palliative care in their patients? An interview study. BMC Fam Pract 2013; 14: 42. doi:10.1186/1471-2296-14-42
    OpenUrlCrossRefPubMed
  54. ↵
    1. Tavares N,
    2. Hunt KJ,
    3. Jarrett N, et al.
    The preferences of patients with chronic obstructive pulmonary disease are to discuss palliative care plans with familiar respiratory clinicians, but to delay conversations until their condition deteriorates: a study guided by interpretative phenomenological analysis. Palliat Med 2020; 34: 1361–1373. doi:10.1177/0269216320937981
    OpenUrl
  55. ↵
    1. Iyer AS,
    2. Dionne-Odom JN,
    3. Ford SM, et al.
    A formative evaluation of patient and family caregiver perspectives on early palliative care in chronic obstructive pulmonary disease across disease severity. Ann Am Thorac Soc 2019; 16: 1024–1033. doi:10.1513/AnnalsATS.201902-112OC
    OpenUrlPubMed
    1. Gysels M,
    2. Higginson IJ
    . Access to services for patients with chronic obstructive pulmonary disease: the invisibility of breathlessness. J Pain Symptom Manage 2008; 36: 451–460. doi:10.1016/j.jpainsymman.2007.11.008
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    1. Fu Y,
    2. Mason A,
    3. Boland AC, et al.
    Palliative care needs and integration of palliative care support in COPD: a qualitative study. Chest 2021; 159: 2222–2232. doi:10.1016/j.chest.2020.12.055
    OpenUrl
  57. ↵
    1. Ahmadi Z,
    2. Sandberg J,
    3. Shannon-Honson A, et al.
    Is chronic breathlessness less recognised and treated compared with chronic pain? A case-based randomised controlled trial. Eur Respir J 2018; 52: 1800887. doi:10.1183/13993003.00887-2018
    OpenUrlAbstract/FREE Full Text
    1. Murray SA,
    2. Boyd K,
    3. Sheikh A
    . Palliative care in chronic illness. BMJ 2005; 330: 611–612. doi:10.1136/bmj.330.7492.611
    OpenUrlFREE Full Text
  58. ↵
    1. Aiken LS,
    2. Butner J,
    3. Lockhart CA, et al.
    Outcome evaluation of a randomized trial of the PhoenixCare intervention: program of case management and coordinated care for the seriously chronically ill. J Palliat Med 2006; 9: 111–126. doi:10.1089/jpm.2006.9.111
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Egan E,
    2. Clavarino A,
    3. Burridge L, et al.
    A randomized control trial of nursing-based case management for patients with chronic obstructive pulmonary disease. Lippincotts Case Manag 2002; 7: 170–179. doi:10.1097/00129234-200209000-00002
    OpenUrlCrossRefPubMed
  60. ↵
    1. Farquhar MC,
    2. Prevost AT,
    3. McCrone P, et al.
    The clinical and cost effectiveness of a Breathlessness Intervention Service for patients with advanced non-malignant disease and their informal carers: mixed findings of a mixed method randomised controlled trial. Trials 2016; 17: 185. doi:10.1186/s13063-016-1304-6
    OpenUrlPubMed
  61. ↵
    1. Higginson IJ,
    2. Bausewein C,
    3. Reilly CC, et al.
    An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2: 979–987. doi:10.1016/S2213-2600(14)70226-7
    OpenUrl
  62. ↵
    1. Scheerens C,
    2. Pype P,
    3. Van Cauwenberg J, et al.
    Early integrated palliative home care and standard care for end-stage COPD (EPIC): a phase II pilot RCT testing feasibility, acceptability, and effectiveness. J Pain Symptom Manage 2020; 59: 206–224. doi:10.1016/j.jpainsymman.2019.09.012
    OpenUrl
  63. ↵
    1. Brumley R,
    2. Enguidanos S,
    3. Jamison P, et al.
    Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007; 55: 993–1000. doi:10.1111/j.1532-5415.2007.01234.x
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    1. Engelhardt JB,
    2. McClive-Reed KP,
    3. Toseland RW, et al.
    Effects of a program for coordinated care of advanced illness on patients, surrogates, and healthcare costs: a randomized trial. Am J Manag Care 2006; 12: 93–100.
    OpenUrlPubMedWeb of Science
  65. ↵
    1. Ateş G,
    2. Ebenau AF,
    3. Busa C, et al.
    ‘Never at ease’ – family carers within integrated palliative care: a multinational, mixed method study. BMC Palliat Care 2018; 17: 39. doi:10.1186/s12904-018-0291-7
    OpenUrlPubMed
    1. Booth S,
    2. Farquhar M,
    3. Gysels M, et al.
    The impact of a breathlessness intervention service (BIS) on the lives of patients with intractable dyspnea: a qualitative phase 1 study. Palliat Support Care 2006; 4: 287–293. doi:10.1017/S1478951506060366
    OpenUrlCrossRefPubMed
    1. Brumley RD,
    2. Enguidanos S,
    3. Cherin DA
    . Effectiveness of a home-based palliative care program for end-of-life. J Palliat Med 2003; 6: 715–724. doi:10.1089/109662103322515220
    OpenUrlCrossRefPubMed
  66. ↵
    1. Farquhar M,
    2. Higginson IJ,
    3. Fagan P, et al.
    Results of a pilot investigation into a complex intervention for breathlessness in advanced chronic obstructive pulmonary disease (COPD): brief report. Palliat Support Care 2010; 8: 143–149. doi:10.1017/S1478951509990897
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Farquhar MC,
    2. Higginson IJ,
    3. Fagan P, et al.
    The feasibility of a single-blinded fast-track pragmatic randomised controlled trial of a complex intervention for breathlessness in advanced disease. BMC Palliat Care 2009; 8: 9. doi:10.1186/1472-684X-8-9
    OpenUrlCrossRefPubMed
    1. Gillis D,
    2. Demmons J,
    3. Rocker G
    . Expanding The INSPIRED COPD Outreach Program™ to the emergency department: a feasibility assessment. Int J Chron Obstruct Pulmon Dis 2017; 12: 1597–1604. doi:10.2147/COPD.S136183
    OpenUrl
    1. Horton R,
    2. Rocker G,
    3. Dale A, et al.
    Implementing a palliative care trial in advanced COPD: a feasibility assessment (the COPD IMPACT study). J Palliat Med 2013; 16: 67–73. doi:10.1089/jpm.2012.0285
    OpenUrlCrossRefPubMed
  68. ↵
    1. Huntley C,
    2. Hakkak F,
    3. Ward H
    . Palliative care for chronic respiratory disease: integrated care in outpatient settings. Br J Community Nurs 2020; 25: 132–138. doi:10.12968/bjcn.2020.25.3.132
    OpenUrl
  69. ↵
    1. Hyden KF,
    2. Coats HL,
    3. Meek PM
    . Home-based palliative care: perspectives of chronic obstructive pulmonary disease patients and their caregivers. Chronic Obstr Pulm Dis 2020; 7: 327–335. doi:10.15326/jcopdf.7.4.2020.0144
    OpenUrl
    1. Johnston B,
    2. Coole C,
    3. Jay Narayanasamy M
    . An end-of-life care nurse service for people with COPD and heart failure: stakeholders’ experiences. Int J Palliat Nurs 2016; 22: 549–559. doi:10.12968/ijpn.2016.22.11.549
    OpenUrl
  70. ↵
    1. Mc Veigh C,
    2. Reid J,
    3. Larkin P, et al.
    The experience of palliative care service provision for people with non-malignant respiratory disease and their family carers: an all-Ireland qualitative study. J Adv Nurs 2018; 74: 383–394. doi:10.1111/jan.13453
    OpenUrl
  71. ↵
    1. Rabow MW,
    2. Dibble SL,
    3. Pantilat SZ, et al.
    The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med 2004; 164: 83–91. doi:10.1001/archinte.164.1.83
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Rabow MW,
    2. Petersen J,
    3. Schanche K, et al.
    The comprehensive care team: a description of a controlled trial of care at the beginning of the end of life. J Palliat Med 2003; 6: 489–499. doi:10.1089/109662103322144862
    OpenUrlCrossRefPubMed
  73. ↵
    1. Rabow MW,
    2. Schanche K,
    3. Petersen J, et al.
    Patient perceptions of an outpatient palliative care intervention: ‘It had been on my mind before, but I did not know how to start talking about death…’. J Pain Symptom Manage 2003; 26: 1010–1015. doi:10.1016/j.jpainsymman.2003.03.002
    OpenUrlCrossRefPubMedWeb of Science
  74. ↵
    1. Rocker GM,
    2. Amar C,
    3. Laframboise WL, et al.
    Spreading improvements for advanced COPD care through a Canadian collaborative. Int J Chron Obstruct Pulmon Dis 2017; 12: 2157–2164. doi:10.2147/COPD.S140043
    OpenUrl
    1. Rosenfeld K,
    2. Rasmussen J
    . Palliative care management: a Veterans Administration demonstration project. J Palliat Med 2003; 6: 831–839. doi:10.1089/109662103322515428
    OpenUrlCrossRefPubMed
    1. Smallwood N,
    2. Currow D,
    3. Booth S, et al.
    Attitudes to specialist palliative care and advance care planning in people with COPD: a multi-national survey of palliative and respiratory medicine specialists. BMC Palliat Care 2018; 17: 115. doi:10.1186/s12904-018-0371-8
    OpenUrlPubMed
  75. ↵
    1. Mc Veigh C,
    2. Reid J,
    3. Larkin P, et al.
    The provision of generalist and specialist palliative care for patients with non-malignant respiratory disease in the North and Republic of Ireland: a qualitative study. BMC Palliat Care 2017; 17: 6. doi:10.1186/s12904-017-0220-1
    OpenUrlPubMed
  76. ↵
    1. Janssens JP,
    2. Weber C,
    3. Herrmann FR, et al.
    Can early introduction of palliative care limit intensive care, emergency and hospital admissions in patients with severe chronic obstructive pulmonary disease? A pilot randomized study. Respiration 2019; 97: 406–415. doi:10.1159/000495312
    OpenUrl
  77. ↵
    1. Smallwood N,
    2. Moran T,
    3. Thompson M, et al.
    Integrated respiratory and palliative care leads to high levels of satisfaction: a survey of patients and carers. BMC Palliat Care 2019; 18: 7. doi:10.1186/s12904-019-0390-0
    OpenUrl
  78. ↵
    1. Smallwood N,
    2. Thompson M,
    3. Warrender-Sparkes M, et al.
    Integrated respiratory and palliative care may improve outcomes in advanced lung disease. ERJ Open Res 2018; 4: 00102-2017. doi:10.1183/23120541.00102-2017
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Bajwah S,
    2. Ross JR,
    3. Wells AU, et al.
    Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference intervention. Thorax 2015; 70: 830–839. doi:10.1136/thoraxjnl-2014-206583
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Lindell KO,
    2. Olshansky E,
    3. Song MK, et al.
    Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010; 39: 304–313. doi:10.1016/j.hrtlng.2009.08.005
    OpenUrlCrossRefPubMedWeb of Science
  81. ↵
    1. Lindell KO,
    2. Klein SJ,
    3. Veatch MS, et al.
    Nurse-led palliative care clinical trial improves knowledge and preparedness in caregivers of patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc 2021; 18: 1811–1821. doi:10.1513/AnnalsATS.202012-1494OC
    OpenUrlPubMed
  82. ↵
    1. Archibald N,
    2. Bakal JA,
    3. Richman-Eisenstat J, et al.
    Early integrated palliative care bundle impacts location of death in interstitial lung disease: a pilot retrospective study. Am J Hosp Palliat Care 2021; 38: 104–113. doi:10.1177/1049909120924995
    OpenUrlPubMed
  83. ↵
    1. Barratt SL,
    2. Morales M,
    3. Speirs T, et al.
    Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Respir Res 2018; 5: e000360. doi:10.1136/bmjresp-2018-000360
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Bischoff KE,
    2. Choi S,
    3. Su A, et al.
    Better together: a mixed-methods study of palliative care co-management for patients with interstitial lung disease. J Palliat Med 2021; 24: 1823–1832. doi:10.1089/jpm.2020.0787
    OpenUrl
    1. Kalluri M,
    2. Claveria F,
    3. Ainsley E, et al.
    Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. J Pain Symptom Manage 2018; 55: 420–426. doi:10.1016/j.jpainsymman.2017.10.016
    OpenUrlPubMed
  85. ↵
    1. Pooler C,
    2. Richman-Eisenstat J,
    3. Kalluri M
    . Early integrated palliative approach for idiopathic pulmonary fibrosis: a narrative study of bereaved caregivers’ experiences. Palliat Med 2018; 32: 1455–1464. doi:10.1177/0269216318789025
    OpenUrlPubMed
  86. ↵
    1. Houben CHM,
    2. Spruit MA,
    3. Luyten H, et al.
    Cluster-randomised trial of a nurse-led advance care planning session in patients with COPD and their loved ones. Thorax 2019; 74: 328–336. doi:10.1136/thoraxjnl-2018-211943
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Sinclair C,
    2. Auret KA,
    3. Evans SF, et al.
    Advance care planning uptake among patients with severe lung disease: a randomised patient preference trial of a nurse-led, facilitated advance care planning intervention. BMJ Open 2017; 7: e013415. doi:10.1136/bmjopen-2016-013415
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Meehan E,
    2. Foley T,
    3. Kelly C, et al.
    Advance care planning for individuals with chronic obstructive pulmonary disease: a scoping review of the literature. J Pain Symptom Manage 2020; 59: 1344–1361. doi:10.1016/j.jpainsymman.2019.12.010
    OpenUrl
  89. ↵
    1. Sørensen AR,
    2. Marsaa K,
    3. Prior TS, et al.
    Attitude and barriers in palliative care and advance care planning in nonmalignant chronic lung disease: results from a Danish national survey. J Palliat Care 2020; 35: 232–235. doi:10.1177/0825859720936012
    OpenUrlPubMed
  90. ↵
    1. Broese JM,
    2. de Heij AH,
    3. Janssen DJ, et al.
    Effectiveness and implementation of palliative care interventions for patients with chronic obstructive pulmonary disease: a systematic review. Palliat Med 2021; 35: 486–502. doi:10.1177/0269216320981294
    OpenUrl
  91. ↵
    1. Disler RT,
    2. Currow DC,
    3. Phillips JL, et al.
    Interventions to support a palliative care approach in patients with chronic obstructive pulmonary disease: an integrative review. Int J Nurs Stud 2012; 49: 1443–1458. doi:10.1016/j.ijnurstu.2012.02.004
    OpenUrlCrossRefPubMed
  92. ↵
    1. Mathews G,
    2. Johnston B
    . Palliative and end-of-life care for adults with advanced chronic obstructive pulmonary disease: a rapid review focusing on patient and family caregiver perspectives. Curr Opin Support Palliat Care 2017; 11: 315–327. doi:10.1097/SPC.0000000000000303
    OpenUrlPubMed
  93. ↵
    1. Crawford GB,
    2. Brooksbank MA,
    3. Brown M, et al.
    Unmet needs of people with end-stage chronic obstructive pulmonary disease: recommendations for change in Australia. Intern Med J 2013; 43: 183–190. doi:10.1111/j.1445-5994.2012.02791.x
    OpenUrlCrossRefPubMed
  94. ↵
    1. Fusi-Schmidhauser T,
    2. Riglietti A,
    3. Froggatt K, et al.
    Palliative care provision for patients with advanced chronic obstructive pulmonary disease: a systematic integrative literature review. COPD 2018; 15: 600–611. doi:10.1080/15412555.2019.1566893
    OpenUrl
  95. ↵
    1. Fusi-Schmidhauser T,
    2. Froggatt K,
    3. Preston N
    . Palliative care integration for patients with advanced chronic obstructive pulmonary disease (COPD): identifying essential components using participatory action research. Palliat Med 2021; 35: 1933–1940. doi:10.1177/02692163211028972
    OpenUrl
  96. ↵
    1. Ora L,
    2. Mannix J,
    3. Morgan L, et al.
    Nurse-led integration of palliative care for chronic obstructive pulmonary disease: an integrative literature review. J Clin Nurs 2019; 28: 3725–3733. doi:10.1111/jocn.15001
    OpenUrl
  97. ↵
    1. Goodridge D,
    2. Duggleby W,
    3. Gjevre J, et al.
    Caring for critically ill patients with advanced COPD at the end of life: a qualitative study. Intensive Crit Care Nurs 2008; 24: 162–170. doi:10.1016/j.iccn.2008.01.002
    OpenUrlCrossRefPubMed
  98. ↵
    1. Oishi A,
    2. Murtagh FE
    . The challenges of uncertainty and interprofessional collaboration in palliative care for non-cancer patients in the community: a systematic review of views from patients, carers and health-care professionals. Palliat Med 2014; 28: 1081–1098. doi:10.1177/0269216314531999
    OpenUrlCrossRefPubMed
  99. ↵
    1. Payne S,
    2. Eastham R,
    3. Hughes S, et al.
    Enhancing integrated palliative care: what models are appropriate? A cross-case analysis. BMC Palliat Care 2017; 16: 64. doi:10.1186/s12904-017-0250-8
    OpenUrlPubMed
  100. ↵
    1. Philip J,
    2. Crawford G,
    3. Brand C, et al.
    A conceptual model: redesigning how we provide palliative care for patients with chronic obstructive pulmonary disease. Palliat Support Care 2018; 16: 452–460. doi:10.1017/S147895151700044X
    OpenUrl
  101. ↵
    1. den Herder-van der Eerden M,
    2. Hasselaar J,
    3. Payne S, et al.
    How continuity of care is experienced within the context of integrated palliative care: a qualitative study with patients and family caregivers in five European countries. Palliat Med 2017; 31: 946–955. doi:10.1177/0269216317697898
    OpenUrlCrossRefPubMed
  102. ↵
    1. Igai Y
    . A narrative literature review of palliative care regarding patients with idiopathic pulmonary fibrosis. Nurs Open 2018; 5: 536–545. doi:10.1002/nop2.163
    OpenUrl
  103. ↵
    1. Lee JYT,
    2. Tikellis G,
    3. Corte TJ, et al.
    The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review. Eur Respir Rev 2020; 29: 190125. doi:10.1183/16000617.0125-2019
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Johnson MJ,
    2. Jamali A,
    3. Ross J, et al.
    Psychometric validation of the needs assessment tool: progressive disease in interstitial lung disease. Thorax 2018; 73: 880–883. doi:10.1136/thoraxjnl-2017-210911
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Kim JW,
    2. Atkins C,
    3. Wilson AM
    . Barriers to specialist palliative care in interstitial lung disease: a systematic review. BMJ Support Palliat Care 2019; 9: 130–138. doi:10.1136/bmjspcare-2018-001575
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Reigada C,
    2. Papadopoulos A,
    3. Boland JW, et al.
    Implementation of the Needs Assessment Tool for patients with interstitial lung disease (NAT:ILD): facilitators and barriers. Thorax 2017; 72: 1049–1051. doi:10.1136/thoraxjnl-2016-209768
    OpenUrlAbstract/FREE Full Text
  107. ↵
    1. Kalluri M,
    2. Younus S,
    3. Archibald N, et al.
    Action plans in idiopathic pulmonary fibrosis: a qualitative study – ‘I do what I can do'. BMJ Support Palliat Care 2021; in press [https://doi.org/10.1136/bmjspcare-2020-002831]. doi: 10.1136/bmjspcare-2020-002831
  108. ↵
    1. Back AL,
    2. Young JP,
    3. McCown E, et al.
    Abandonment at the end of life from patient, caregiver, nurse, and physician perspectives: loss of continuity and lack of closure. Arch Intern Med 2009; 169: 474–479. doi:10.1001/archinternmed.2008.583
    OpenUrlCrossRefPubMedWeb of Science
  109. ↵
    1. Kim JW,
    2. Olive S,
    3. Jones S, et al.
    Interstitial lung disease and specialist palliative care access: a healthcare professionals survey. BMJ Support Palliat Care 2022; 12: e748–e751. doi:10.1136/bmjspcare-2019-002148
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Gardener AC,
    2. Ewing G,
    3. Mendonca S, et al.
    Support Needs Approach for Patients (SNAP) tool: a validation study. BMJ Open 2019; 9: e032028. doi:10.1136/bmjopen-2019-032028
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Murtagh FE,
    2. Ramsenthaler C,
    3. Firth A, et al.
    A brief, patient- and proxy-reported outcome measure in advanced illness: validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS). Palliat Med 2019; 33: 1045–1057. doi:10.1177/0269216319854264
    OpenUrlPubMed
  112. ↵
    1. Gadoud A,
    2. Kane E,
    3. Oliver SE, et al.
    Palliative care for non-cancer conditions in primary care: a time trend analysis in the UK (2009–2014). BMJ Support Palliat Care 2020; in press [https://doi.org/10.1136/bmjspcare-2019-001833]. doi: 10.1136/bmjspcare-2019-001833
  113. ↵
    1. Carlucci A,
    2. Vitacca M,
    3. Malovini A, et al.
    End-of-life discussion, patient understanding and determinants of preferences in very severe COPD patients: a multicentric study. COPD 2016; 13: 632–638. doi:10.3109/15412555.2016.1154034
    OpenUrl
  114. ↵
    1. Singer AE,
    2. Goebel JR,
    3. Kim YS, et al.
    Populations and interventions for palliative and end-of-life care: a systematic review. J Palliat Med 2016; 19: 995–1008. doi:10.1089/jpm.2015.0367
    OpenUrlCrossRefPubMed
  115. ↵
    1. van Gurp J,
    2. van Selm M,
    3. van Leeuwen E, et al.
    Teleconsultation for integrated palliative care at home: a qualitative study. Palliat Med 2016; 30: 257–269. doi:10.1177/0269216315598068
    OpenUrlCrossRefPubMed
  116. ↵
    1. Hjorth NE,
    2. Schaufel MA,
    3. Sigurdardottir KR, et al.
    Feasibility and acceptability of introducing advance care planning on a thoracic medicine inpatient ward: an exploratory mixed method study. BMJ Open Respir Res 2020; 7: e000485. doi:10.1136/bmjresp-2019-000485
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Pang SM,
    2. Tse CY,
    3. Chan KS, et al.
    An empirical analysis of the decision-making of limiting life-sustaining treatment for patients with advanced chronic obstructive pulmonary disease in Hong Kong, China. J Crit Care 2004; 19: 135–144. doi:10.1016/j.jcrc.2004.08.001
    OpenUrlCrossRefPubMedWeb of Science
  118. ↵
    1. Ora L,
    2. Mannix J,
    3. Morgan L, et al.
    Chronic obstructive pulmonary disease and advance care planning: a synthesis of qualitative literature on patients’ experiences. Chronic Illn 2022; 18: 221–233. doi:10.1177/1742395321990109
    OpenUrl
  119. ↵
    1. Sinclair C,
    2. Auret KA,
    3. Evans SF, et al.
    Impact of a nurse-led advance care planning intervention on satisfaction, health-related quality of life, and health care utilization among patients with severe respiratory disease: a randomized patient-preference trial. J Pain Symptom Manage 2020; 59: 848–855. doi:10.1016/j.jpainsymman.2019.11.018
    OpenUrlPubMed
  120. ↵
    1. Momen N,
    2. Hadfield P,
    3. Kuhn I, et al.
    Discussing an uncertain future: end-of-life care conversations in chronic obstructive pulmonary disease. A systematic literature review and narrative synthesis. Thorax 2012; 67: 777–780. doi:10.1136/thoraxjnl-2012-201835
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Stephen N,
    2. Skirton H,
    3. Woodward V, et al.
    End-of-life care discussions with nonmalignant respiratory disease patients: a systematic review. J Palliat Med 2013; 16: 555–565. doi:10.1089/jpm.2012.0442
    OpenUrlCrossRefPubMed
  122. ↵
    1. Jabbarian LJ,
    2. Zwakman M,
    3. van der Heide A, et al.
    Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices. Thorax 2018; 73: 222–230. doi:10.1136/thoraxjnl-2016-209806
    OpenUrlAbstract/FREE Full Text
  123. ↵
    1. Grossman D,
    2. Katz A,
    3. Lock K, et al.
    A retrospective study reviewing interprofessional advance care planning group discussions in pulmonary rehabilitation: a proof-of-concept and feasibility study. J Palliat Care 2021; 36: 219–223. doi:10.1177/0825859719896421
    OpenUrl
  124. ↵
    1. Tavares N,
    2. Jarrett N,
    3. Hunt K, et al.
    Palliative and end-of-life care conversations in COPD: a systematic literature review. ERJ Open Res 2017; 3: 00068-2016. doi:10.1183/23120541.00068-2016
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Meehan E,
    2. Sweeney C,
    3. Foley T, et al.
    Advance care planning in COPD: guidance development for healthcare professionals. BMJ Support Palliat Care 2022; 12: e302–e310. doi: 10.1136/bmjspcare-2019-002002
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Burgess Kelleher A,
    2. Sweeney C,
    3. Foley T, et al.
    An e-Delphi study to identify priority areas for education on advance care planning in COPD management. Respir Care 2020; 65: 347–354. doi:10.4187/respcare.07072
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Sobanski PZ,
    2. Alt-Epping B,
    3. Currow DC, et al.
    Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 2020; 116: 12–27. doi:10.1093/cvr/cvz200
    OpenUrlPubMed
  128. ↵
    1. Sullivan DR,
    2. Iyer AS,
    3. Enguidanos S, et al.
    Palliative care early in the care continuum among patients with serious respiratory illness: an official ATS/AAHPM/HPNA/SWHPN policy statement. Am J Respir Crit Care Med 2022; 206: e44–e69. doi:10.1164/rccm.202207-1262ST
    OpenUrl
  129. ↵
    1. Houben CHM,
    2. Spruit MA,
    3. Groenen MTJ, et al.
    Efficacy of advance care planning: a systematic review and meta-analysis. J Am Med Dir Assoc 2014; 15: 477–489. doi:10.1016/j.jamda.2014.01.008
    OpenUrlCrossRefPubMed
  130. ↵
    1. van Steijn D,
    2. Pons Izquierdo JJ,
    3. Garralda Domezain E, et al.
    Population's potential accessibility to specialized palliative care services: a comparative study in three European countries. Int J Environ Res Public Health 2021; 18: 10345. doi:10.3390/ijerph181910345
    OpenUrl
  131. ↵
    1. Arias-Casais N,
    2. López-Fidalgo J,
    3. Garralda E, et al.
    Trends analysis of specialized palliative care services in 51 countries of the WHO European region in the last 14 years. Palliat Med 2020; 34: 1044–1056. doi:10.1177/0269216320931341
    OpenUrlPubMed
  132. ↵
    1. Stajduhar KI,
    2. Mollison A,
    3. Giesbrecht M, et al.
    ‘Just too busy living in the moment and surviving’: barriers to accessing health care for structurally vulnerable populations at end-of-life. BMC Palliat Care 2019; 18: 11. doi:10.1186/s12904-019-0396-7
    OpenUrlCrossRef
  133. ↵
    1. Currow DC,
    2. Allingham S,
    3. Bird S, et al.
    Referral patterns and proximity to palliative care inpatient services by level of socio-economic disadvantage. A national study using spatial analysis. BMC Health Serv Res 2012; 12: 424. doi:10.1186/1472-6963-12-424
    OpenUrlPubMed
  134. ↵
    1. Sudore RL,
    2. Lum HD,
    3. You JJ, et al.
    Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel. J Pain Symptom Manage 2017; 53: 821–832. doi:10.1016/j.jpainsymman.2016.12.331
    OpenUrlCrossRefPubMed
  135. ↵
    1. Miyashita J,
    2. Shimizu S,
    3. Shiraishi R, et al.
    Culturally adapted consensus definition and action guideline: Japan's advance care planning. J Pain Symptom Manage 2022; 64: 602–613. doi:10.1016/j.jpainsymman.2022.09.005
    OpenUrl
  136. ↵
    1. Ernecoff NC,
    2. Check D,
    3. Bannon M, et al.
    Comparing specialty and primary palliative care interventions: analysis of a systematic review. J Palliat Med 2020; 23: 389–396. doi:10.1089/jpm.2019.0349
    OpenUrlPubMed
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 2 Table of Contents
European Respiratory Journal: 62 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease
Daisy J.A. Janssen, Sabrina Bajwah, Michele Hilton Boon, Courtney Coleman, David C. Currow, Albert Devillers, Chantal Vandendungen, Magnus Ekström, Ron Flewett, Sarah Greenley, Mai-Britt Guldin, Cristina Jácome, Miriam J. Johnson, Geana Paula Kurita, Matthew Maddocks, Alda Marques, Hilary Pinnock, Steffen T. Simon, Thomy Tonia, Kristoffer Marsaa
European Respiratory Journal Aug 2023, 62 (2) 2202014; DOI: 10.1183/13993003.02014-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease
Daisy J.A. Janssen, Sabrina Bajwah, Michele Hilton Boon, Courtney Coleman, David C. Currow, Albert Devillers, Chantal Vandendungen, Magnus Ekström, Ron Flewett, Sarah Greenley, Mai-Britt Guldin, Cristina Jácome, Miriam J. Johnson, Geana Paula Kurita, Matthew Maddocks, Alda Marques, Hilary Pinnock, Steffen T. Simon, Thomy Tonia, Kristoffer Marsaa
European Respiratory Journal Aug 2023, 62 (2) 2202014; DOI: 10.1183/13993003.02014-2022
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Tweetable abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

ERS Official Documents

  • ERS statement: frailty in adults with chronic lung disease
  • ERS statement: airway clearance techniques in adults with bronchiectasis
Show more ERS Official Documents

ERS guidelines

  • ERS statement: frailty in adults with chronic lung disease
  • ERS statement: airway clearance techniques in adults with bronchiectasis
  • ERS Clinical Practice Guideline on palliative care in COPD or ILD
Show more ERS guidelines

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society